ESMO 2023 | SWOG S1801: pathologic response in neoadjuvant-adjuvant vs. adjuvant pembro for resectable melanoma

Sapna Patel, MD, from The University of Texas MD Anderson Cancer Center, discusses primary efficacy results from the Phase II SWOG S1801 (NCT03698019) trial, revealing improved event-free survival (EFS) with neoadjuvant-adjuvant pembrolizumab compared to adjuvant pembrolizumab in stage IIIB-IV melanoma. The randomized phase II trial assessed pathologic response as a surrogate marker of clinical outcome. Pathologic response analysis in lymph node specimens showed promising outcomes, with a major pathologic response of 53%. RECIST response data demonstrated a 50% overall response rate (ORR) in neoadjuvant-adjuvant participants. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.